TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance

Author:

Xia Shunjie,Ji Lin,Tao Liye,Pan Yu,Lin Zhongjie,Wan Zhe,Pan Haoqi,Zhao Jie,Cai Liuxin,Xu Junjie,Cai XiujunORCID

Funder

China Postdoctoral Science Foundation

Zhejiang Province Natural Science Foundation

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference60 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma;Gao;Cell,2019

3. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma;Xu;Ann Oncol,2019

4. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma;Xia;EBioMedicine,2020

5. Increasing AR by HIF-2alpha inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals;Xu;Cell Death Disease,2017

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3